CytomX Therapeutics, Inc.
CTMX
NASDAQ·Healthcare·Biotechnology·Mkt cap $807.7M
$3.71
▲ +0.82%
P/E
-8.24
Mkt Cap
$807.7M
52-Wk Range
$1.90–$8.21
52-Week Range
$1.90 - $8.21
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 70.2% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary Probody technology platform enabling conditional activation
- Strategic partnerships with major pharmaceutical companies (BMS, Amgen, Pfizer)
- Diversified pipeline across multiple cancer indications
- Reduced systemic toxicity profile compared to conventional antibody therapeutics
Bear Case
1 risk
- High volatility (beta 2.1). Larger-than-normal price swings expected.
Growth
Strong growth ahead
Clinical trial progression and potential regulatory approvals
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Hot
+26.2% over 3m
Quality
Excellent
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying CTMX right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 5, 2026
AUG 6, 2026
Reported EPS of -$0.09 vs -$0.08 consensus (-16.8% surprise). Revenue of $1.4M vs $12.4M expected (-88.5%).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-16.8%
Revenue trend · last 8Q
—
—
+23%
-26%
-82%
-98%
-80%
-92%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$33.4M
$38.1M
$50.9M
$18.7M
$6.0M
$663.0K
$10.3M
$1.4M
Margins · last 8Q
Gross
0.0%
Operating
—
Profit
-1457.4%
Wall Street consensus
7 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Guggenheim · Aug 10, 2026
vs Industry
How CTMX stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related